ARTES Acquires VLP Technology

October 14, 2010

ARTES Biotechnology (Langenfield, Germany) has acquired the Anavax virus-like particle (VLP) technology from Select Vaccines Ltd. (Melbourne, Australia). Anavax is a patent-protected VLP technology that can be applied to develop vaccines for the prevention of several infectious diseases.

ARTES seeks enhance its vaccine business using Anavax in combination with ARTES’s Hansenula expression system.

The Anavax VLP platform already has been applied to the development of adjuvant-free vaccines against avian and swine flu, malaria, and HIV. The Hansenula expression system is recommended by the World Health Organization for hepatitis B vaccination campaigns. ARTES believes it can combine these platforms to enable low-cost mass production of safe and effective vaccines.